Taysha gene therapies reports second quarter 2024 financial results and provides corporate update

Presented cohort one (low dose) data from both trials of tsha-102 at 2024 irsf rett syndrome scientific meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up to 22 weeks) patients
TSHA Ratings Summary
TSHA Quant Ranking